BiomX Inc. - Common Stock, $0.0001 par value (PHGE)
CUSIP: 09090D301
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Shares outstanding
- 1,527,040
- Total 13F shares
- 10,837,890
- Share change
- -2,461,931
- Total reported value
- $4,876,799
- Price per share
- $0.45
- Number of holders
- 16
- Value change
- -$1,566,731
- Number of buys
- 4
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 09090D301?
CUSIP 09090D301 identifies PHGE - BiomX Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09090D301:
Top shareholders of PHGE - BiomX Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| OrbiMed Israel BioFund GP Limited Partnership |
3/4/5
13D/G
|
10%+ Owner · ORBIMED ISRAEL GP LTD. |
1%
from 13D/G
|
13,777,980
mixed-class rows
|
$5,250,517 | — | 15 May 2024 | |
| James E. Flynn |
3/4/5
|
Director, *Director by Deputization |
—
mixed-class rows
|
5,831,350
mixed-class rows
|
$2,321,016 | — | 21 Apr 2025 | |
| Cystic Fibrosis Foundation |
3/4/5
13D/G
|
10%+ Owner |
10%
from 13D/G
|
11,131,426
mixed-class rows
|
$1,663,688 | — | 26 Feb 2025 | |
| Nantahala Capital Management, LLC |
13D/G
13F
|
Company |
10%
|
2,494,197
|
$1,496,518 | +$420,034 | 31 Mar 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
163%
|
2,494,108
|
$1,385,976 | — | 31 Mar 2025 | |
| Centaurus Investments Ltd |
13D/G
|
Rodney Hodges |
7.6%
|
1,970,403
|
$1,182,242 | $0 | 21 Apr 2025 | |
| Chidozie Ugwumba |
3/4/5
|
Exit Form 4 - former 10% owner |
—
class O/S missing
|
2,997,025
|
$1,018,989 | — | 17 Oct 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
117%
|
1,787,767
|
$993,462 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
104%
|
1,590,738
|
$883,973 | — | 31 Mar 2025 | |
| AIGH Capital Management LLC |
13F
|
Company |
103%
|
1,566,944
|
$870,750 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
62%
|
940,629
|
$522,708 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
58%
|
892,976
|
$496,226 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
28%
|
430,000
|
$238,951 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
26%
|
401,136
|
$222,911 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
20%
|
299,598
|
$166,487 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
16%
|
237,376
|
$131,910 | — | 31 Mar 2025 | |
| Jonathan Eitan Solomon |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
507,248
mixed-class rows
|
$72,246 | — | 14 Apr 2025 | |
| Warberg Asset Management LLC |
13F
|
Company |
6.5%
|
99,616
|
$55,357 | — | 31 Mar 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.98%
|
96,866
|
$53,828 | — | 31 Mar 2025 | |
| Merav Bassan |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
174,597
mixed-class rows
|
$45,370 | — | 14 Apr 2025 | |
| Marina Wolfson |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
163,545
mixed-class rows
|
$39,070 | — | 14 Apr 2025 | |
| BARCLAYS PLC |
13F
|
Company |
1.6%
|
25,000
|
$13,893 | — | 31 Mar 2025 | |
| Assaf Oron |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
263,304
mixed-class rows
|
$9,836 | — | 16 Sep 2024 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
1%
|
15,950
|
$8,863 | — | 31 Mar 2025 | |
| HEIGHTS CAPITAL MANAGEMENT, INC |
13F
|
Company |
0.95%
|
14,497
|
$8,056 | — | 31 Mar 2025 | |
| Paul J. Sekhri |
3/4/5
|
Director |
—
mixed-class rows
|
21,875
mixed-class rows
|
$4,250 | — | 28 Jul 2021 | |
| UBS Group AG |
13F
|
Company |
0.49%
|
7,514
|
$4,178 | — | 31 Mar 2025 | |
| CLEAR STREET LLC |
13F
|
Company |
0.15%
|
2,363
|
$1,313 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.02%
|
300
|
$167 | — | 31 Mar 2025 | |
| Carolina Wealth Advisors, LLC |
13F
|
Company |
0%
|
159
|
$88 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2025 | |
| Dambach Michael E. |
3/4/5
|
Director |
—
class O/S missing
|
41,000
|
— | — | 21 Aug 2023 | |
| Lynne Marie Sullivan |
3/4/5
|
Director |
—
class O/S missing
|
41,000
|
— | — | 01 Mar 2023 | |
| Marks Jason M. |
3/4/5
|
Director |
—
class O/S missing
|
41,000
|
— | — | 21 Aug 2023 | |
| Russell Greig |
3/4/5
|
Director |
—
class O/S missing
|
35,200
|
— | — | 14 Apr 2025 | |
| Gbolahan Amusa |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 29 Mar 2022 | |
| Jonas Grossman |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 29 Mar 2022 | |
| Alan Charles Moses |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Eddie Williams |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Gregory Louis Merril |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Jesse Goodman |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Jonathan S. Leff |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 | |
| Susan Blum |
3/4/5
|
Director |
—
class O/S missing
|
17,600
|
— | — | 14 Apr 2025 |
Institutional Holders of BiomX Inc. - Common Stock, $0.0001 par value (PHGE) as of Q2 2025
As of 30 Jun 2025,
BiomX Inc. - Common Stock, $0.0001 par value (PHGE) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,837,890 shares.
The largest 10 holders included
DEERFIELD MANAGEMENT COMPANY, L.P., Nantahala Capital Management, LLC, MORGAN STANLEY, AIGH Capital Management LLC, Ikarian Capital, LLC, JPMORGAN CHASE & CO, DAFNA Capital Management LLC, ADAR1 Capital Management, LLC, BOOTHBAY FUND MANAGEMENT, LLC, and Warberg Asset Management LLC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
18
Q2 2025 holders
16
Holder diff
-2
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.